From: Postoperative collateral formation after indirect bypass for hemorrhagic moyamoya disease
Characteristics | PCF | p value | OR (95% CI) | ||
---|---|---|---|---|---|
Good (n = 27) | Poor (n = 37) | Uni | Multi a | ||
Age, years | 33.3 ± 13.0 | 38.6 ± 8.3 | 0.066 | 0.067 | 0.948 (0.896–1.004) |
Male sex | 8 (29.6%) | 14 (37.8%) | 0.496 | Â | Â |
History of risk factors | |||||
 Hypertension | 7 (25.9%) | 7 (18.9%) | 0.504 |  |  |
 Smoking | 1 (3.7%) | 3 (8.1%) | 0.483 |  |  |
 Diabetes | 1 (3.7%) | 0 (0.0%) | 1.000 |  |  |
 Alcohol use | 0 (0.0%) | 3 (8.1%) | 0.999 |  |  |
 Hyperlipidemia | 1 (3.7%) | 1 (2.7%) | 0.821 |  |  |
 Thyroid disease | 1 (3.7%) | 2 (5.4%) | 0.752 |  |  |
Type of hemorrhage | |||||
 IVH | 14 (51.9%) | 19 (51.4%) | 0.968 |  |  |
 ICH&IVH | 5 (18.5%) | 10 (27.0%) | 0.430 |  |  |
 ICH | 5 (18.5%) | 8 (21.6%) | 0.824 |  |  |
 SAH | 3 (11.1%) | 0 (0.0%) | 0.999 |  |  |
Hemorrhagic site |  |  | 0.005 | 0.006 | 5.222 (1.605–16.987) |
 Anterior | 20 (74.1%) | 14 (37.8%) |  |  |  |
 Posterior | 7 (25.9%) | 23 (63.2%) |  |  |  |
Suzuki stage | Â | Â | 0.823 | Â | Â |
 II | 4 (14.8%) | 3 (8.1%) |  |  |  |
 III | 12 (44.4%) | 21 (56.8%) |  |  |  |
 IV | 9 (33.3%) | 12 (32.4%) |  |  |  |
 V | 1 (3.7%) | 0 (0.0%) |  |  |  |
 VI | 1 (3.7%) | 1 (2.7%) |  |  |  |
PCA involvement | 8 (29.6%) | 4 (10.8%) | 0.066 | 0.067 | 4.181 (0.906–19.306) |
Collateral circulation | Â | Â | 0.907 | Â | Â |
 Grade I (1–4) | 6 (22.2%) | 7 (18.9%) |  |  |  |
 Grade II (5–8) | 19 (70.4%) | 29 (78.4%) |  |  |  |
 Grade III (9–12) | 2 (7.4%) | 1 (2.7%) |  |  |  |
Dilation of AChA-PCoA | 18 (66.7%) | 30 (81.1%) | 0.193 | Â | Â |
ECA collateral | |||||
 STA collateral | 0 (0.0%) | 1 (2.7%) | 1.000 |  |  |
 MMA collateral | 17 (63.0%) | 19 (51.4%) | 0.356 |  |  |
 OA collateral | 3 (11.1%) | 3 (8.1%) | 0.685 |  |  |
The stage of pre-stroke period | 0.590 | Â | Â | ||
 Normal | 3 (11.1%) | 6 (16.2%) |  |  |  |
 Stage I | 0 (0.0%) | 1 (2.7%) |  |  |  |
 Stage II | 9 (33.3%) | 9 (24.3%) |  |  |  |
 Stage III | 12 (44.4%) | 6 (16.2%) |  |  |  |
 Stage IV | 3 (11.1%) | 15 (40.5%) |  |  |  |
 EDAS surgery | 23 (85.2%) | 30 (81.1%) | 0.668 | 0.998 | 0.998 (0.210–4.742) |